16 results about "T-regulatory cell" patented technology

The present invention provides compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.

The present invention relates to methods for predicting and monitoring of the course of type 1 diabetes with the use of detection of fragments of preproinsulin from sera of the patients, specifically in patients treated with cell therapies with CD4+ Fox P3+ T regulatory cells (in the following Treg cells" or "Tregs"). The present invention relates also to the possibility of the use of the said fragments of preproinsulin in the treatment of patients with type 1 diabetes directly or as agents used during manufacturing of antigen-specific Tregs for the treatment of type 1 diabetes.

The present invention provides thymic T regulatory cells (ThyTreg cells) that encode or alternatively express a chimeric antigen receptor (CAR) comprising an extracellular domain, a hinge region, a transmembrane domain, and an intracellular domain, wherein the intracellular domain comprises a cytoplasmic costimulatory domain having a sequence having at least 85% identity with SEQ ID NO: 1, and a cytoplasmic stimulatory domain. The present invention also provides compositions and uses in immunotherapy.

The invention relates to a safe and feasible triple strategy based on i) a gene-modified T regulatory cell characterised by genetic silencing of CIITA (HLA class II); and one, or two of the HLA class I gene loci HLA-A, HLA-B, and HLA-C; ii) particular embodiments provide a cell modified to have resistance to a particular immunosuppressive drug by gene silencing of the respective target gene; iii) the partial stealth concept combined with immunosuppression facilitates donor recipient matching using AI tools.

To provide methods for preparing compositions enriched in T regulatory cells (Tregs) and methods for treating immunological diseases using the compositions, and to provide methods for preparing compositions enriched in lymphocytes and depleted of Tregs and use of the compositions in treating proliferative diseases.SOLUTION: A method for preparing a composition enriched in CD4+CD25hi T regulatory cells (Tregs) is provided, comprising contacting in vitro a population of human cells including T lymphocytes obtained from a patient-derived human blood or bone marrow sample with a tumor necrotic factor receptor 2 (TNFR2) agonist or an NF-κB activator, thereby preparing the composition in which the Tregs are enriched, wherein the Tregs constitute at least 60% of the cells in the composition.SELECTED DRAWING: None

Providing a binder and a method for using the same. [Solution] The present invention provides conjugates that specifically bind to CD8+KIR+T regulatory cells, and their use in the treatment of diseases or disorders, such as inflammatory diseases, autoimmune diseases, cancer, or infectious diseases. Conjugates and methods of using them to modulate the activity of CD8+KIR+ regulatory T cells (Tregs) are provided herein. The conjugates are bispecific or polyspecific and specifically bind to antigens expressed on the surface of CD8+KIR+Tregs.

Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.

This invention provides compositions and methods for reducing the immunogenicity of cells for transplantation, including cell-based immunotherapy. [Solution] A vector encoding β2-microglobulin (B2M) modified RNA, along with a targeting moiety and other signaling and / or suicide genes, enables the efficient generation of engineered CAR T regulatory cells or other therapeutic cells derived from any source. The present invention provides, for example, vectors encoding β2-microglobulin (B2M) modified RNA and chimeric antigen receptors (CARs).

The present invention includes compositions and methods for treating atherosclerosis. In certain embodiments, atherosclerosis is treated using a chimeric antigen receptor (CAR) T cell specific for modified low-density lipoprotein.

The invention relates to the medicinal product consisting of CD3+CD4+CD25+CD127− T regulatory cells administered intrathecally in the treatment of multiple sclerosis.

Aging progresses at different rates among individuals, underscoring the need for better indicators of functional decline. The inventors showed that the T cell energy metabolism in the elderly reveals that high mitochondrial oxidative phosphorylation, especially in CD4 T regulatory cells, is associated with a reduced probability of being frail / prefrail, independent of age, sex, or comorbidities. When mitochondrial respiration drops below a critical threshold, it adversely affects intrinsic capacity. Furthermore, a low level of oxidative phosphorylation in CD4 T helper cells, particularly in central and effector memory subsets, was significantly associated with a faster decline in intrinsic capacity over time, suggesting that T cell mitochondrial bioenergetics represents a key biomarker for managing functional decline in older adults. Accordingly, the present invention relates to a method for determining the risk of age-related functional decline in a subject comprising the step of measuring the mitochondrial dependency in a population of T cells wherein the mitochondrial dependency (MitoDep) correlates with the age-related functional decline.

The present disclosure provides engineered IL-15 muteins and fusion proteins comprising the same, and uses thereof. The present disclosure also provides compositions and methods for delivering cytokines to particular cells, as well as fusion proteins that specifically bind to CD8+KIR+ T regulatory cells and further comprise a cytokine such as a IL-15. Also provided are treatments for diseases or disorders, such as an inflammatory disease, an autoimmune disease, cancer, or an infectious disease.

Immunotherapy leverages the body's immune system to target cancer cells, but some tumors resist this treatment due to low infiltration of T CD8+ cells and high infiltration of regulatory T cells in the tumor microenvironment. The inventors showed that a JAK inhibitor (i.e. ruxolitinib) reshapes the tumor immune microenvironment resulting in T regulatory cells reduction and T CD8+ cells increase. Ruxolitinib-mediated immune microenvironment effects create new therapeutic opportunities by enhancing anti-PD1 treatment efficacy in cSCC and melanoma and other immunotherapy resistant cancer types such as pancreatic cancer and acute myeloid leukemia (AML). Cell-based immunotherapy response is also improved in AML. Accordingly, the present invention relates to the use of JAK inhibitors for enhancing the potency of immunotherapy.

The present disclosure provides engineered IL-15 muteins and fusion proteins comprising the same, and uses thereof. The present disclosure also provides compositions and methods for delivering cytokines to particular cells, as well as fusion proteins that specifically bind to CD8+KIR+ T regulatory cells and further comprise a cytokine such as a IL-15. Also provided are treatments for diseases or disorders, such as an inflammatory disease, an autoimmune disease, cancer, or an infectious disease.

The present invention relates to methods for monitoring and for assessing the efficacy of, respectfully, cell therapies of patients treated with CD4+ Fox P3+ T regulatory cells. Further subject matter relates to cell therapeutic methods using CD4+ Fox P3+ T regulatory cells and the monitoring methods of the invention.

This disclosure describes a novel approach that specifically modulates the activity and / or the number of intratumoral regulatory T (Treg) cells in a subject. Such an approach can be used to reduce the number of intratumoral T regulatory cells in a subject as well as to inhibit tumor growth in a subject having a cancer without eliciting autoimmune responses.